sb 202190 has been researched along with Learning Disabilities in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Learning Disabilities: Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, S | 1 |
| Zhou, G | 1 |
| Liu, H | 1 |
| Zhang, B | 1 |
| Li, J | 1 |
| Cui, R | 1 |
| Du, Y | 1 |
1 other study available for sb 202190 and Learning Disabilities
| Article | Year |
|---|---|
Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia.
Topics: Animals; Apoptosis; Caspase 3; Dementia, Vascular; Disease Models, Animal; Gene Expression Regulatio | 2013 |